These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

100 related articles for article (PubMed ID: 3138098)

  • 21. Long-term benefits of continuous subcutaneous insulin infusion in children with Type 1 diabetes: a 4-year follow-up.
    Sulli N; Shashaj B
    Diabet Med; 2006 Aug; 23(8):900-6. PubMed ID: 16911629
    [TBL] [Abstract][Full Text] [Related]  

  • 22. [Pharmacokinetics of insulin administered subcutaneously. Application to treatment by portable pump (1)].
    Scheen AJ
    Diabete Metab; 1989; 15(3):128-38. PubMed ID: 2668053
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Diabetic ketoacidosis in pregnancy resulting from insulin pump failure. A case report.
    Lindenbaum C; Menzin A; Ludmir J
    J Reprod Med; 1993 Apr; 38(4):306-8. PubMed ID: 8501740
    [TBL] [Abstract][Full Text] [Related]  

  • 24. [Coincidence of hepatic angiosarcoma and insulin-resistance diabetes mellitus with high-dose intraperitoneal insulin therapy].
    Kersten A; Schwarzkopf J; Petersen KG; Lohner M
    Verh Dtsch Ges Pathol; 1994; 78():285-7. PubMed ID: 7534000
    [TBL] [Abstract][Full Text] [Related]  

  • 25. [Present role of continuous subcutaneous insulin infusion (CSII) by insulin pump in the treatment of diabetes mellitus].
    Pfützner A; Berger S; Spinas G
    Schweiz Med Wochenschr; 2000 Dec; 130(48):1854-61. PubMed ID: 11132530
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Clinical experience in human diabetics with portable and implantable insulin minipumps.
    Mirouze J; Selam JL; Slingeneyer A; Chaptal PA; Hedon B; Mares P; Franetzki M; Prestele K; Millet P; Beraud JJ
    Life Support Syst; 1983; 1(1):39-49. PubMed ID: 6678370
    [TBL] [Abstract][Full Text] [Related]  

  • 27. [Treatment of insulin-dependent diabetes mellitus by insulin pump in children under 7 years of age].
    Joseph MG; Ginies JL; Chomienne F; Limal JM
    Arch Fr Pediatr; 1992; 49(6):505-10. PubMed ID: 1449351
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Impaired endothelial antithrombotic activity following short-term interruption of continuous subcutaneous insulin infusion in type 1 diabetic patients.
    Iorio A; Federici MO; Mourvaki E; Ferolla P; Piroddi M; Stabile A; Timi A; Celleno R; Benedetti MM
    Thromb Haemost; 2007 Sep; 98(3):635-41. PubMed ID: 17849053
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Metabolic control with insulin pump therapy: the Waikato experience.
    Reda E; Von Reitzenstein A; Dunn P
    N Z Med J; 2007 Jan; 120(1248):U2401. PubMed ID: 17277817
    [TBL] [Abstract][Full Text] [Related]  

  • 30. [Assessment of metabolic control and safety of continuous subcutaneous insulin infusion in prepubertal children with type 1 diabetes mellitus].
    Minkina-Pedras M; Jarosz-Chobot P; Małecka-Tendera E; Deja G
    Endokrynol Diabetol Chor Przemiany Materii Wieku Rozw; 2005; 11(3):171-6. PubMed ID: 16232370
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Successful treatment of extremely brittle, insulin-dependent diabetes with a novel subcutaneous insulin pump regimen.
    Nathan DM
    Diabetes Care; 1982; 5(2):105-10. PubMed ID: 6821487
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Acute complications associated with insulin infusion pump therapy. Report of experience with 161 patients.
    Mecklenburg RS; Benson EA; Benson JW; Fredlund PN; Guinn T; Metz RJ; Nielsen RL; Sanner CA
    JAMA; 1984 Dec; 252(23):3265-9. PubMed ID: 6439896
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Extreme subcutaneous insulin resistance: a misunderstood syndrome.
    Soudan B; Girardot C; Fermon C; Verlet E; Pattou F; Vantyghem MC
    Diabetes Metab; 2003 Nov; 29(5):539-46. PubMed ID: 14631332
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Insulin underdelivery from implanted pumps using peritoneal route. Determinant role of insulin pump compatibility.
    Renard E; Bouteleau S; Jacques-Apostol D; Lauton D; Gibert-Boulet F; Costalat G; Bringer J; Jaffiol C
    Diabetes Care; 1996 Aug; 19(8):812-7. PubMed ID: 8842596
    [TBL] [Abstract][Full Text] [Related]  

  • 35. A remotely programmable insulin delivery system. Successful short-term implantation in man.
    Schade DS; Eaton RP; Edwards WS; Doberneck RC; Spencer WJ; Carlson GA; Bair RE; Love JT; Urenda RS; Gaona JI
    JAMA; 1982 Apr; 247(13):1848-53. PubMed ID: 7038166
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Subcutaneous peritoneal access device for type I diabetic patients nonresponsive to subcutaneous insulin.
    Schade DS; Eaton RP; Warhol RM; Gregory JA; Doberneck RC
    Diabetes; 1982 May; 31(5 Pt 1):470-3. PubMed ID: 7152135
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Local skin reaction caused by the plastic catheter tubing of the continuous subcutaneous insulin infusion system.
    Nguyen TV; Burnett JW
    Cutis; 1988 May; 41(5):355-6. PubMed ID: 3371087
    [TBL] [Abstract][Full Text] [Related]  

  • 38. The programmable implantable medication system (PIMS): design features and pre-clinical trials.
    Saudek CD; Fischell RE; Swindle MM
    Horm Metab Res; 1990 Apr; 22(4):201-6. PubMed ID: 2190901
    [TBL] [Abstract][Full Text] [Related]  

  • 39. [Ketoacidosis during ambulatory treatment by continuous subcutaneous infusion of insulin. Possible role of catheter infection].
    Leguerrier AM; Allannic H; Lorcy Y
    Presse Med; 1984 Apr; 13(16):1008. PubMed ID: 6232520
    [No Abstract]   [Full Text] [Related]  

  • 40. Implanted programmable insulin pumps: one hundred fifty-three patient years of surgical experience.
    Udelsman R; Chen H; Loman K; Pitt HA; Saudek CD
    Surgery; 1997 Dec; 122(6):1005-11. PubMed ID: 9426413
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 5.